New agents, new treatment, and antiemetic therapy.
With the introduction of newer antineoplastic agents, the challenge for supportive care is enlarging. For the most part, these targeted therapies are given in addition to more classic anticancer drugs, either in combination or in sequence, underscoring the need for prevention of emesis and attention to all treatment toxicities. Strategies for preventing these side effects need to be investigated while appropriately addressing more familiar problems such as emesis. Two directions for improving emetic control are clear. First is the development of newer antiemetics that enhance current control rates, and second is the proper use of existing agents in all emetic settings. This report outlines the rationale behind the development of neurokinin type 1 antagonists, and reviews consensus recommendations in the prevention of acute and delayed emesis.
Gralla
Richard J
RJ
Division of Medical Oncology, Department of Medicine, Columbia University, Herbert Irving Comprehensive Cancer Center, New York, NY 10032, USA.
D000932:Antiemetics / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D064729:Neurokinin-1 Receptor Antagonists; D017410:Practice Guidelines as Topic; D018040:Receptors, Neurokinin-1 / Q000502:physiology; D013997:Time Factors; D014839:Vomiting / Q000139:chemically induced* / Q000188:drug therapy / Q000517:prevention & control
D000932:Antiemetics; D000970:Antineoplastic Agents; D064729:Neurokinin-1 Receptor Antagonists; D018040:Receptors, Neurokinin-1